Cargando…

A diastereoselective synthesis of Cebranopadol, a novel analgesic showing NOP/mu mixed agonism

A diastereoselective synthesis of the title compound as a single E diastereomer has been efficiently accomplished by assembling the featured pyrano-indole scaffold of the spiro[cyclohexane-dihydropyrano[3,4-b]-indole]-amine framework through an oxa-Pictet-Spengler reaction, promoted by a cheap and g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fantinati, Anna, Bianco, Sara, Guerrini, Remo, Salvadori, Severo, Pacifico, Salvatore, Cerlesi, Maria Camilla, Calo, Girolamo, Trapella, Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445067/ https://www.ncbi.nlm.nih.gov/pubmed/28546566 http://dx.doi.org/10.1038/s41598-017-02502-9

Ejemplares similares

Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist
por: Rizzi, Anna, et al.
Publicado: (2016)

Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo)
por: Bird, Mark F., et al.
Publicado: (2016)

Structure- and conformation-activity studies of nociceptin/orphanin FQ receptor dimeric ligands
por: Pacifico, Salvatore, et al.
Publicado: (2017)

NOP receptor pharmacological profile – A dynamic mass redistribution study
por: Malfacini, Davide, et al.
Publicado: (2018)

In vitro pharmacological characterization of a novel unbiased NOP receptor‐selective nonpeptide agonist AT‐403
por: Ferrari, Federica, et al.
Publicado: (2017)

In vitro and in vivo pharmacological characterization of a neuropeptide S tetrabranched derivative
por: Ruzza, Chiara, et al.
Publicado: (2015)

Novel Mixed NOP/Opioid Receptor Peptide Agonists
por: Pacifico, Salvatore, et al.
Publicado: (2021)

Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic
por: Kleideiter, Elke, et al.
Publicado: (2017)

Biased Agonism at Nociceptin/Orphanin FQ Receptors: A Structure Activity Study on N/OFQ(1–13)-NH(2)
por: Pacifico, Salvatore, et al.
Publicado: (2020)

Biased versus Partial Agonism in the Search for Safer Opioid Analgesics
por: Azevedo Neto, Joaquim, et al.
Publicado: (2020)

Correction to: Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic
por: Kleideiter, Elke, et al.
Publicado: (2018)

Synergistic interaction between the agonism of cebranopadol at nociceptin/orphanin FQ and classical opioid receptors in the rat spinal nerve ligation model
por: Christoph, Thomas, et al.
Publicado: (2018)

Functional Selectivity Does Not Predict Antinociceptive/Locomotor Impairing Potencies of NOP Receptor Agonists
por: Azevedo Neto, Joaquim, et al.
Publicado: (2021)

Structure–Activity Relationship Studies on Oxazolo[3,4-a]pyrazine Derivatives Leading to the Discovery of a Novel Neuropeptide S Receptor Antagonist with Potent In Vivo Activity
por: Albanese, Valentina, et al.
Publicado: (2021)

In vitro sepsis induces Nociceptin/Orphanin FQ receptor (NOP) expression in primary human vascular endothelial but not smooth muscle cells
por: Bird, Mark F., et al.
Publicado: (2022)

Cebranopadol, a Mixed Opioid Agonist, Reduces Cocaine Self-administration through Nociceptin Opioid and Mu Opioid Receptors
por: Shen, Qianwei, et al.
Publicado: (2017)

Cebranopadol as a Novel Promising Agent for the Treatment of Pain
por: Ziemichod, Wojciech, et al.
Publicado: (2022)

Biased agonism: the quest for the analgesic holy grail
por: Stanczyk, M. Alexander, et al.
Publicado: (2018)

Effects of Cebranopadol on Cocaine-induced Hyperactivity and Cocaine Pharmacokinetics in Rats
por: Wei, Huimei, et al.
Publicado: (2020)

C7β-Methyl Analogues of the Orvinols: The Discovery of Kappa Opioid Antagonists with Nociceptin/Orphanin FQ Peptide (NOP) Receptor Partial Agonism and Low, or Zero, Efficacy at Mu Opioid Receptors
por: Cueva, Juan Pablo, et al.
Publicado: (2015)

(L)-Monomethyl Tyrosine (Mmt): New Synthetic Strategy via Bulky ‘Forced-Traceless’ Regioselective Pd-Catalyzed C(sp(2))–H Activation
por: Illuminati, Davide, et al.
Publicado: (2023)

MOP and NOP receptor interaction: Studies with a dual expression system and bivalent peptide ligands
por: Bird, M. F., et al.
Publicado: (2022)

Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial
por: Christoph, Annette, et al.
Publicado: (2017)

Nociceptin/Orphanin FQ (N/OFQ) conjugated to ATTO594: a novel fluorescent probe for the N/OFQ (NOP) receptor
por: Bird, M F, et al.
Publicado: (2018)

Cebranopadol: A First-in-Class Nociceptin Receptor Agonist for Managing Chronic Pain
por: Nair, Abhijit S, et al.
Publicado: (2020)

A Proteomic Screen for Nucleolar SUMO Targets Shows SUMOylation Modulates the Function of Nop5/Nop58
por: Westman, Belinda J., et al.
Publicado: (2010)

Design and Synthesis of (99m)TcN-Labeled Dextran-Mannose Derivatives for Sentinel Lymph Node Detection
por: Boschi, Alessandra, et al.
Publicado: (2018)

Synthesis, Biological Activity and Molecular Docking of Chimeric Peptides Targeting Opioid and NOP Receptors
por: Wtorek, Karol, et al.
Publicado: (2022)

Bispecific sigma-1 receptor antagonism and mu-opioid receptor partial agonism: WLB-73502, an analgesic with improved efficacy and safety profile compared to strong opioids
por: Vidal-Torres, Alba, et al.
Publicado: (2023)

Sometimes, the Least Demanding Solution Is the Most Suitable: A Careful Survey of NMR Spectra of a Phosphonium Salt Accounted for Its “Unusual Wittig Reaction”
por: Fantinati, Anna, et al.
Publicado: (2018)

The Fascinating Chemistry of α‐Haloamides
por: Fantinati, Anna, et al.
Publicado: (2020)

Quantitative Systems Pharmacology and Biased Agonism at Opioid Receptors: A Potential Avenue for Improved Analgesics
por: Bedini, Andrea, et al.
Publicado: (2022)

Structure of the Nociceptin/Orphanin FQ Receptor in Complex with a Peptide Mimetic
por: Thompson, Aaron A., et al.
Publicado: (2012)

Assessment of the Abuse Potential of Cebranopadol in Nondependent Recreational Opioid Users: A Phase 1 Randomized Controlled Study
por: Göhler, Karin, et al.
Publicado: (2019)

Parkinson’s disease: no NOP, new hope
por: Arcuri, Ludovico, et al.
Publicado: (2016)

Molecular mechanism of agonism and inverse agonism in ghrelin receptor
por: Qin, Jiao, et al.
Publicado: (2022)

CB1 Agonism Alters Addiction-Related Behaviors in Mice Lacking Mu or Delta Opioid Receptors
por: Roeckel, Laurie-Anne, et al.
Publicado: (2018)

Discovery of Novel Fetal Hemoglobin Inducers through Small Chemical Library Screening
por: Breveglieri, Giulia, et al.
Publicado: (2020)

Biased agonism
por: Kenakin, Terry
Publicado: (2009)

Agonizing Hedgehog
por: Weitzman, Jonathan B
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_0khoujroojketqleken3hcrv1a